Nidan Laboratories & Healthcare Limited Stock Price Today (NSE: NIDAN)
Nidan Laboratories & Healthcare Limited
Fundamental Score
Nidan Laboratories & Healthcare Limited Share Price Live NSE/BSE & Institutional Fundamental Analysis
Nidan Laboratories & Healthcare Limited share price today is ₹14.60, up +0.00% on NSE/BSE as of 18 March 2026. Nidan Laboratories & Healthcare Limited (NIDAN) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹30.72 (Cr). The 52-week high for NIDAN share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 13.30x, NIDAN is currently trading below its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 2.92% and a debt-to-equity ratio of 0.18.
Nidan Laboratories & Healthcare Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Nidan Laboratories & Healthcare Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Nidan Laboratories & Healthcare Share Price: A Financial Stability Analysis
The healthcare service provider industry often sees valuations buoyed by consistent demand, irrespective of broader economic cycles. However, individual company performance hinges on efficient operations and strategic expansion. This analysis provides an overview of the financial stability of Nidan Laboratories & Healthcare Limited, focusing on key metrics impacting the Nidan Laboratories & Healthcare share price, currently trading at ₹16.799999. We will examine the Price-to-Earnings (PE) ratio, Return on Capital Employed (ROCE), and contextualize these figures with peer performance.
Nidan Laboratories & Healthcare Limited currently has a PE ratio of 13.3. This suggests that the market is valuing the company at 13.3 times its earnings per share. While PE ratios provide a snapshot of relative valuation, a thorough assessment requires comparing it to sector peers and historical data.
The company's ROCE of 6.17% is a critical indicator of its efficiency in generating profits from its capital employed. A lower ROCE compared to industry benchmarks may indicate less effective asset utilization or higher operating costs. This impacts the company's "moat" or competitive advantage. A robust ROCE would signal a strong moat; however, 6.17% suggests Nidan faces challenges in generating superior returns compared to its cost of capital. This aspect needs further investigation to determine if it’s a temporary dip or a structural weakness.
Comparing Nidan Laboratories & Healthcare Limited with its peers, such as
Suraksha Diagnostic Ltd, requires a multi-faceted approach. While quantitative metrics are crucial, assessing management quality and strategic direction is equally important. For instance, evaluating Suraksha Diagnostic Ltd's capital allocation strategies and market penetration tactics might offer valuable insights into Nidan's relative positioning. Ultimately, a holistic understanding of the competitive landscape is vital to assess Nidan's long-term viability.This analysis forms part of a comprehensive 80-parameter fundamental audit of Nidan Laboratories & Healthcare Limited. This audit was verified by Sweta Mishra. The information presented here is observational and based on publicly available data. It is not intended as investment advice. Potential investors should conduct their own due diligence before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Nidan Laboratories & Healthcare Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NIDAN across key market metrics for learning purposes.
Positive Indicators
8 factors identified
Strong Operating Margins (29.75%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 13.30 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (30.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.60%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Profit Growth Track Record (22.52% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.18)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (57.04%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (2.92%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.17%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (2.76% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Nidan Laboratories & Healthcare Limited Financial Statements
Comprehensive financial data for Nidan Laboratories & Healthcare Limited including income statement, balance sheet and cash flow
About NIDAN (Nidan Laboratories & Healthcare Limited)
Nidan Laboratories & Healthcare Limited (NIDAN) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Healthcare Service Provider sector with a current market capitalisation of ₹30.72 (Cr). Nidan Laboratories & Healthcare Limited has delivered a Return on Equity (ROE) of 2.92% and a ROCE of 6.17%. The debt-to-equity ratio stands at 0.18, reflecting the company's capital structure. Investors tracking NIDAN share price can monitor key metrics including P/E ratio, promoter holding of 57.04%, and quarterly earnings growth.
Company Details
NIDAN Share Price: Frequently Asked Questions
What is the current share price of Nidan Laboratories & Healthcare Limited (NIDAN)?
As of 18 Mar 2026, 10:22 am IST, Nidan Laboratories & Healthcare Limited share price is ₹14.60. The NIDAN stock has a market capitalisation of ₹30.72 (Cr) on NSE/BSE.
Is NIDAN share price Overvalued or Undervalued?
NIDAN share price is currently trading at a P/E ratio of 13.30x, compared to the industry average of 39.28x. Based on this relative valuation, the Nidan Laboratories & Healthcare Limited stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of NIDAN share price?
The 52-week high of NIDAN share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Nidan Laboratories & Healthcare Limited share price?
Key factors influencing NIDAN share price include quarterly earnings growth (Sales Growth: 24.60%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Nidan Laboratories & Healthcare Limited a good stock for long-term investment?
Nidan Laboratories & Healthcare Limited shows a 5-year Profit Growth of 22.52% and an ROE of 2.92%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.18 before investing in NIDAN shares.
How does Nidan Laboratories & Healthcare Limited compare with its industry peers?
Nidan Laboratories & Healthcare Limited competes with major peers in the Healthcare Service Provider. Investors should compare NIDAN share price P/E of 13.30x and ROE of 2.92% against the industry averages to determine competitive standing.
What is the P/E ratio of NIDAN and what does it mean?
NIDAN share price has a P/E ratio of 13.30x compared to the industry average of 39.28x. Investors pay ₹13 for every ₹1 of annual earnings.
How is NIDAN performing according to Bull Run's analysis?
NIDAN has a Bull Run fundamental score of 62.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does NIDAN belong to?
NIDAN operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Nidan Laboratories & Healthcare Limited share price.
What is Return on Equity (ROE) and why is it important for NIDAN?
NIDAN has an ROE of 2.92%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Nidan Laboratories & Healthcare Limited generates profits from shareholders capital.
How is NIDAN debt-to-equity ratio and what does it indicate?
NIDAN has a debt-to-equity ratio of 0.18, which indicates conservative financing with low financial risk.
What is NIDAN dividend yield and is it a good dividend stock?
NIDAN offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Nidan Laboratories & Healthcare Limited shares.
How has NIDAN share price grown over the past 5 years?
NIDAN has achieved 5-year growth rates of: Sales Growth 2.76%, Profit Growth 22.52%, and EPS Growth 14.48%.
What is the promoter holding in NIDAN and why does it matter?
Promoters hold 57.04% of NIDAN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Nidan Laboratories & Healthcare Limited.
What is NIDAN market capitalisation category?
NIDAN has a market capitalisation of ₹31 crores, placing it in the Small-cap category.
How volatile is NIDAN stock?
NIDAN has a beta of N/A. A beta > 1 suggests the Nidan Laboratories & Healthcare Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is NIDAN operating profit margin trend?
NIDAN has a 5-year average Operating Profit Margin (OPM) of 29.75%, indicating the company's operational efficiency.
How is NIDAN quarterly performance?
Recent quarterly performance shows Nidan Laboratories & Healthcare Limited YoY Sales Growth of 24.60% and YoY Profit Growth of 30.00%.
What is the institutional holding pattern in NIDAN?
NIDAN has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Nidan Laboratories & Healthcare Limited stock.